All Title Author
Keywords Abstract

PLOS ONE  2012 

Association of OX40L Polymorphisms with Sporadic Breast Cancer in Northeast Chinese Han Population

DOI: 10.1371/journal.pone.0041277

Full-Text   Cite this paper   Add to My Lib

Abstract:

OX40L is an important costimulatory molecule that plays a crucial role in the regulation of T-cell-mediated immunity. The interaction of OX40-OX40L is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. The genetic variants of OX40L can increase the risk of SLE, atherosclerosis, systemic sclerosis and show gender-specific effects in some studies. Accordingly, we performed a case-control study including 557 breast cancer patients and 580 age- and sex-matched healthy controls to investigate whether single nucleotide polymorphisms (SNPs) in the OX40L gene are associated with sporadic breast cancer susceptibility and progression in Chinese Han women. Seven SNPs of OX40L (rs6661173, rs1234313, rs3850641, rs1234315, rs12039904, rs844648 and rs10912580) were genotyped with the method of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The results indicated that rs3850641G allele could increase the susceptibility to breast cancer (P = 0.009662), even in the validation study (P = 0.0001515). A significant association between rs3850641 and breast cancer risk was observed under the additive model and dominant model (P = 0.01042 and 0.01942, respectively). The haplotype analysis showed that haplotype Ars844648Ars10912580 was significantly associated with breast cancer, even after 10,000 permutations for haplotypes in block only (P = 0.0003). In clinicopathologic features analysis, the association between rs1234315 and C-erbB2 status was significant (P = 0.02541). Our data primarily indicates that rs3850641 of OX40L gene contributes to sporadic breast carcinogenesis in a northeast Chinese Han population.

References

[1]  Stuber E, Neurath M, Calderhead D, Fell HP, Strober W (1995) Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2: 507–521.
[2]  Murata K, Ishii N, Takano H, Miura S, Ndhlovu LC, et al. (2000) Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 191: 365–374.
[3]  Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, et al. (1997) Expression and function of OX40 ligand on human dendritic cells. J Immunol 159: 3838–3848.
[4]  Kashiwakura J, Yokoi H, Saito H, Okayama Y (2004) T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol 173: 5247–5257.
[5]  Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, et al. (1996) The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 183: 2185–2195.
[6]  Ito T, Wang YH, Duramad O, Hanabuchi S, Perng OA, et al. (2006) OX40 ligand shuts down IL-10-producing regulatory T cells. Proc Natl Acad Sci U S A 103: 13138–13143.
[7]  Duan W, So T, Croft M (2008) Antagonism of airway tolerance by endotoxin/lipopolysaccharide through promoting OX40L and suppressing antigen-specific Foxp3+ T regulatory cells. J Immunol 181: 8650–8659.
[8]  Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, et al. (2000) Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164: 2160–2169.
[9]  Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140: 883–899.
[10]  Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674.
[11]  Coughlin SS, Ekwueme DU (2009) Breast cancer as a global health concern. Cancer Epidemiol 33: 315–318.
[12]  Ali SA, Ahmad M, Lynam J, McLean CS, Entwisle C, et al. (2004) Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine 22: 3585–3594.
[13]  Pedroza-Gonzalez A, Xu K, Wu TC, Aspord C, Tindle S, et al. (2011) Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 208: 479–490.
[14]  Cunninghame Graham DS, Graham RR, Manku H, Wong AK, Whittaker JC, et al. (2008) Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat Genet 40: 83–89.
[15]  Gourh P, Arnett FC, Tan FK, Assassi S, Divecha D, et al. (2010) Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis 69: 550–555.
[16]  Wang X, Ria M, Kelmenson PM, Eriksson P, Higgins DC, et al. (2005) Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 37: 365–372.
[17]  Bossini-Castillo L, Broen JC, Simeon CP, Beretta L, Vonk MC, et al. (2011) A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis 70: 638–641.
[18]  Chang YK, Yang W, Zhao M, Mok CC, Chan TM, et al. (2009) Association of BANK1 and TNFSF4 with systemic lupus erythematosus in Hong Kong Chinese. Genes Immun 10: 414–420.
[19]  Delgado-Vega AM, Abelson AK, Sanchez E, Witte T, D’Alfonso S, et al. (2009) Replication of the TNFSF4 (OX40L) promoter region association with systemic lupus erythematosus. Genes Immun 10: 248–253.
[20]  Mashimo Y, Suzuki Y, Hatori K, Tabara Y, Miki T, et al. (2008) Association of TNFRSF4 gene polymorphisms with essential hypertension. J Hypertens 26: 902–913.
[21]  Stuber E, Strober W (1996) The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 183: 979–989.
[22]  Liu YJ, Soumelis V, Watanabe N, Ito T, Wang YH, et al. (2007) TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol 25: 193–219.
[23]  Morris A, Vetto JT, Ramstad T, Funatake CJ, Choolun E, et al. (2001) Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res Treat 67: 71–80.
[24]  Ria M, Lagercrantz J, Samnegard A, Boquist S, Hamsten A, et al. (2011) A common polymorphism in the promoter region of the TNFSF4 gene is associated with lower allele-specific expression and risk of myocardial infarction. PLoS One 6: e17652.
[25]  Yamaguchi S, Yamada Y, Metoki N, Yoshida H, Satoh K, et al. (2006) Genetic risk for atherothrombotic cerebral infarction in individuals stratified by sex or conventional risk factors for atherosclerosis. Int J Mol Med 18: 871–883.
[26]  Malarstig A, Eriksson P, Rose L, Diehl KA, Hamsten A, et al. (2008) Genetic variants of tumor necrosis factor superfamily, member 4 (TNFSF4), and risk of incident atherothrombosis and venous thromboembolism. Clin Chem 54: 833–840.
[27]  Fish EN (2008) The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 8: 737–744.
[28]  Lin PY, Sun L, Thibodeaux SR, Ludwig SM, Vadlamudi RK, et al. (2010) B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol 185: 2747–2753.
[29]  Takeda I, Ine S, Killeen N, Ndhlovu LC, Murata K, et al. (2004) Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 172: 3580–3589.
[30]  Vu MD, Xiao X, Gao W, Degauque N, Chen M, et al. (2007) OX40 costimulation turns off Foxp3+ Tregs. Blood 110: 2501–2510.
[31]  Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, et al. (2008) OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 68: 5206–5215.
[32]  Smirnov DA, Cheung VG (2008) ATM gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs. Am J Hum Genet 83: 243–253.
[33]  Ramos PS, Criswell LA, Moser KL, Comeau ME, Williams AH, et al. (2011) A comprehensive analysis of shared loci between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals limited genetic overlap. PLoS Genet 7: e1002406.
[34]  Shukla PC, Singh KK, Quan A, Al-Omran M, Teoh H, et al. (2011) BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nat Commun 2: 593.
[35]  Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–137.
[36]  Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
[37]  Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, et al. (2007) Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25: 4772–4778.
[38]  Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW (2008) An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107: 309–330.

Full-Text

comments powered by Disqus